The INFUSE - Anterior Myocardial Infarction (AMI) Study
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452
subjects enrolled in up to 50 US and European sites. Subjects who present with anterior
ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior
descending (LAD) with TIMI 0/1/2 flow will be eligible for randomization to one of the
following arms:
1. Local infusion of abciximab following thrombus aspiration
2. Local infusion of abciximab and no thrombus aspiration
3. No local infusion and thrombus aspiration
4. No local infusion and no thrombus aspiration
In addition, a cardiac magnetic resonance imaging (MRI) sub-study evaluating microvascular
obstruction (MVO) will be performed with up to 160 subjects at up to 20 sites.
Phase:
N/A
Details
Lead Sponsor:
Atrium Medical Corporation
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments